Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 7/20 | 0.43 |
| ▸ | CYP1B1 | Q16678 | 6/20 | 0.43 |
| ▸ | CA1 | P00915 | 2/20 | 0.41 |
| ▸ | CA9 | Q16790 | 2/20 | 0.41 |
| ▸ | CYP1A1 | P04798 | 6/20 | 0.40 |
| ▸ | CYP2B6 | P20813 | 2/20 | 0.36 |
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | CA3 | P07451 | 1/20 | 0.32 |
| ▸ | CA4 | P22748 | 1/20 | 0.32 |
| ▸ | CA6 | P23280 | 1/20 | 0.32 |
| ▸ | CA5A | P35218 | 1/20 | 0.32 |
| ▸ | CA7 | P43166 | 1/20 | 0.32 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.32 |
| ▸ | SOST | Q9BQB4 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.32 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.32 |
| ▸ | STS | P08842 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29207958 | 0.73 | CYP1A2 (0.58) | CYP1A2CYP1B1CA9CYP1A1CYP2B6 | |
| SCHEMBL4614504 | 0.68 | — | — | |
| SCHEMBL9464450 | 0.67 | KDM4E (0.54) | CYP1A2CA1CA9CYP2B6CA12 | |
| SCHEMBL12477741 | 0.65 | CA1 (0.33) | CYP1A2CYP1B1CA1CA9CYP1A1 | |
| SCHEMBL8487842 | 0.64 | CA1 (0.32) | CA1CA9CA12CA2LMNA | |
| SCHEMBL10712969 | 0.63 | CA1 (0.32) | CYP1A2CYP1B1CA1CA9STS | |
| SCHEMBL277261 | 0.60 | CYP2B6 (0.46) | CYP1A2CYP1B1CA1CA9CYP1A1 | |
| SCHEMBL7485477 | 0.60 | PKM (0.48) | CYP1A2CYP1B1CA1CA9CYP1A1 | |
| Furan-2(5H)-One SCHEMBL25302 | 0.60 | — | — | |
| SCHEMBL2781166 | 0.58 | CA1 (0.44) | CA1CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110224170-A1 | Pyranopyranone derivatives as antimicrobial agents | BASF SE (DE) | 2011-09-15 | — | — | US | claimed |
| WO-2011107411-A1 | PYRANOPYRANONE DERIVATIVES AS ANTIMICROBIAL AGENTS | BASF SE (DE) | 2011-09-09 | — | — | WO | claimed |
| JP-10330268-A | — | — | None | — | — | JP | disclosed |
| CN-115414480-A | Dianhydrogalactitol in combination with radiation for treatment of non-small cell lung cancer and glioblastoma multiforme | 德玛医药 | 2022-12-02 | — | — | CN | disclosed |
| EP-3115052-B1 | D-PSICOSE FOR USE IN THE TREATMENT OF ARTERIOSCLEROSIS | MATSUTANI KAGAKU KOGYO KK (JP) | 2019-08-21 | — | — | EP | disclosed |
| EP-3175858-A1 | THERAPEUTIC USE OF D-ALLOSE FOR THE TREATMENT OF LIVER CANCER OR SKIN CANCER | Matsutani Chemical Industry Co., Ltd. (JP) | 2017-06-07 | — | — | EP | disclosed |
| EP-3115052-A1 | D-PSICOSE FOR USE IN THE TREATMENT OF ARTERIOSCLEROSIS | Matsutani Chemical Industry Co., Ltd. (JP) | 2017-01-11 | — | — | EP | disclosed |
| US-8420606-B2 | Method of utilizing physiological activity of rare saccharide and composition containing rare saccharide | FUSHIMI PHARMACEUTICAL CO., LTD. (JP) | 2013-04-16 | — | — | US | disclosed |
| WO-2011131474-A2 | SKIN-GENTLE DEODORANTS AND ANTIPERSPIRANTS | HENKEL AG & CO. KGAA (DE) | 2011-10-27 | — | — | WO | disclosed |
| EP-2370177-A2 | NOVEL COSMETIC COMPOSITIONS HAVING HAIR GROWTH INHIBITING EFFECT | Henkel AG & Co. KGaA (DE) | 2011-10-05 | — | — | EP | disclosed |
| EP-2370050-A2 | NOVEL DEODORANTS AND ANTIPERSPIRANTS HAVING HAIR GROWTH INHIBITING EFFECT | Henkel AG & Co. KGaA (DE) | 2011-10-05 | — | — | EP | disclosed |
| WO-2009007257-A2 | ADVANCED GLYCATION END PRODUCTS AS ACTIVE INGREDIENTS | HENKEL AG & CO. KGAA (DE) | 2009-01-15 | — | — | WO | disclosed |
| US-20050245459-A1 | Method of utilizing physiological activity of rare saccharide and composition containing rare saccharide | Fushimi Pharmaceutical Co. Ltd. (JP) | 2005-11-03 | — | — | US | disclosed |
| EP-1538200-A1 | METHOD OF UTILIZING PHYSIOLOGICAL ACTIVITY OF RARE SACCHARIDE AND COMPOSITIONS CONTAINING RARE SACCHARIDE | Fushimi Pharmaceutical Company, Limited (JP) | 2005-06-08 | — | — | EP | disclosed |
| JP-H10330268-A | AGENT FOR INHIBITING SYNTHESIS OF PYRANOPYRANONE COMPOUND-CONTAINING HSP47 | KUREHA CHEM IND CO LTD | 1998-12-15 | — | — | JP | disclosed |
| US-4198426-A | 2-Substituted-3-methyl-γ-pyrone tricyclic derivatives | AYERST MCKENNA & HARRISON LTD. (CA) | 1980-04-15 | — | — | US | disclosed |
| US-4189490-A | 2-Substituted-3-methyl-γ-pyrone tricyclic derivatives | AYERST MCKENNA & HARRISON LIMITED (CA) | 1980-02-19 | — | — | US | disclosed |
| US-4177284-A | 2-Substituted-3-methyl-γ-pyrone tricvclic derivatives and process therefor | AYERST MCKENNA & HARRISON LTD. (CA) | 1979-12-04 | — | — | US | disclosed |
| US-4105778-A | ANTIALLERGENS, BACTERICIDES, FUNGICIDES | AYERST, MCKENNA & HARRISON, LTD. (CA) | 1978-08-08 | — | — | US | disclosed |
| US-4060619-A | ANTIALLERGY, MICROBIOCIDE | AYERST MCKENNA AND HARRISON LTD. (CA) | 1977-11-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110224170-A1 | Pyranopyranone derivatives as antimicrobial agents | NR1H2, CBR3, NR1H3 | CYP1A2 976/4885CYP1B1 706/4885CA1 3872/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.